Table 2.
Relationship between the expression of TIM-3 and clinicopathological parameters
| TIM-3 | P value | ||
|---|---|---|---|
| Positive | Negative | ||
| Total | 92 (56.4) | 71 (43.6) | |
| Age, n (%) | 0.987 | ||
| < 70y | 83 (90.2) | 64 (90.1) | |
| ≥ 70y | 9 (9.8) | 7 (9.9) | |
| Gender, n (%) | 0.259 | ||
| Male | 57 (53.3) | 50 (46.7) | |
| Female | 35 (62.5) | 21 (37.5) | |
| ISUP, n (%) | 0.055 | ||
| < 4 | 67 (79.8) | 40 (65.6) | |
| ≥ 4 | 17 (20.2) | 21 (34.4) | |
| Histological Type, n(%) | 0.377 | ||
| ccRCC | 74 (58.3) | 53 (41.7) | |
| Non-ccRCC | 18 (50.0) | 18 (50.0) | |
| Pathology, n (%) | |||
| Sarcoma | 5 (62.5) | 3 (37.5) | 0.898 |
| Necrosis | 20 (66.7) | 10 (33.3) | 0.958 |
| Nephrectomy | 0.026 | ||
| Yes | 84 (61.3) | 53 (38.7) | |
| No | 7 (35.0) | 13 (65.0) | |
| ECOG, n (%) | 0.239 | ||
| 0–1 | 68 (60.7) | 44 (39.3) | |
| ≥ 2 | 20 (50.0) | 20 (50.0) | |
| IMDC, n (%) | 0.030 | ||
| Low | 23 (69.7) | 10 (30.3) | |
| Intermediate | 49 (61.3) | 31 (38.7) | |
| High | 11 (37.9) | 18 (62.1) | |
| T stage, n (%) | 0.391 | ||
| < 2b | 38 (64.4) | 20 (55.6) | |
| ≥ 2b | 21 (35.6) | 16 (44.4) | |
| Treatment, n (%) | |||
| Cytokine | 12 (54.5) | 10 (45.5) | 0.762 |
| Targeted therapy | 32 (50.0) | 32 (50.0) | 0.088 |
| Radiotherapy | 7 (50.0) | 7 (50.0) | 0.504 |
| Chemotherapy | 5 (62.5) | 3 (37.5) | 0.817 |